The Center for Biosimilars® recaps the top news for the week of May 6, 2019.
Transcript:
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 6.
Number 5: Last week, Coherus BioSciences announced that it has reached a settlement with Amgen over a trade secret case. Separately, Amgen filed a new complaint against Samsung Bioepis.
Number 4: The pan-Canadian Pharmaceutical Alliance and Cancer Care Ontario have partnered to create a new biosimilars initiative.
Number 3: Now that its comment period has closed, the FDA has heard from a variety of stakeholders who asked the agency to reconsider its guidance on biosimilar naming.
Number 2: A new review of the available literature on switching sought to address provider concerns about biosimilars.
Number 1: The idea of giving the Federal Trade Commission more authority to cut through patent thickets blocking biosimilar competition was raised during a hearing of the Senate Judiciary Committee.
Finally, last week, our e-newsletter asked whether you agree with a recent proposal that suggests regulating biologics’ prices rather than continuing to develop the US biosimilars market.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.